Does HER2 status influence in the benefit of ramucirumab and paclitaxel as second line treatment of advanced gastro-esophageal adenocarcinoma? Data from the AGAMENON-SEOM registry.

MLA

Valcarcel, Sena, et al. “Does HER2 Status Influence in the Benefit of Ramucirumab and Paclitaxel as Second Line Treatment of Advanced Gastro-Esophageal Adenocarcinoma? Data from the AGAMENON-SEOM Registry.” Journal of Cancer Research & Clinical Oncology, vol. 149, no. 7, July 2023, pp. 4077–89. EBSCOhost, https://doi.org/10.1007/s00432-022-04294-6.

APA

Valcarcel, S., Gallego, J., Jimenez-Fonseca, P., Diez, M., de Castro, E. M., Hernandez, R., Arrazubi, V., Custodio, A., Cano, J. M., Montes, A. F., Macias, I., Visa, L., Calvo, A., Tocino, R. V., Lago, N. M., Limón, M. L., Granja, M., Gil, M., Pimentel, P., & Macia-Rivas, L. (2023). Does HER2 status influence in the benefit of ramucirumab and paclitaxel as second line treatment of advanced gastro-esophageal adenocarcinoma? Data from the AGAMENON-SEOM registry. Journal of Cancer Research & Clinical Oncology, 149(7), 4077–4089. https://doi.org/10.1007/s00432-022-04294-6

Chicago

Valcarcel, Sena, Javier Gallego, Paula Jimenez-Fonseca, Marc Diez, Eva Martínez de Castro, Raquel Hernandez, Virginia Arrazubi, et al. 2023. “Does HER2 Status Influence in the Benefit of Ramucirumab and Paclitaxel as Second Line Treatment of Advanced Gastro-Esophageal Adenocarcinoma? Data from the AGAMENON-SEOM Registry.” Journal of Cancer Research & Clinical Oncology 149 (7): 4077–89. doi:10.1007/s00432-022-04294-6.